AI-powered fundus cameras have been installed at all Cleveland Clinic Cole Eye Institute locations next to primary care ...
Positive topline results from the phase 3 GLOW2 trial suggest that tarcocimab tedromer (Zenkuda), an investigational anti–vascular endothelial growth factor (VEGF) biologic, may offer durable disease ...
AI-based screening for glaucoma can be implemented in primary care within existing screening programmes, enhancing efficiency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results